Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGoing up a dose on Mounjaro is a clinical decision, not a milestone you hit automatically. The right time is typically after four weeks at your current dose, once side effects have settled and your prescriber is satisfied you're tolerating it well. No single number on the scales triggers the move — readiness matters more than speed. Mounjaro (tirzepatide) is a prescription-only medicine; a prescriber assesses your progress before any dose change, as described in the NHS's patient guidance on tirzepatide.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen contains four 2.5mg doses. That starter dose exists for one reason: to let your body adjust. It is not expected to drive significant weight loss on its own, and that trips people up. They finish four weeks, see modest results, and assume the treatment isn't working. It is, it's just not at a therapeutic level yet. The adjustment phase is doing its job quietly in the background.
After four weeks at 2.5mg, the licensed titration schedule moves to 5mg. Whether you actually make that step depends on a clinical review. A prescriber at a regulated service like ours will look at how you've tolerated the first month: any ongoing nausea, digestive disruption, or other symptoms that haven't yet settled. If things feel manageable, escalation makes sense. If you're still in the thick of side effects, holding at 2.5mg for another four weeks is a reasonable, entirely normal outcome, not a setback.
The move to 5mg is where most people begin to notice appetite changes more clearly. Giving yourself a stable four weeks there before considering the next step is the standard approach, as set out in Mounjaro's licensed dosing schedule.
There is no blood test or scan that tells you to go up. The signals are practical. On the "ready" side: gut symptoms from the current dose have largely resolved; you've completed at least four full weeks; and your prescriber has reviewed your progress. That review is not a formality. At nume, a GPhC-registered prescriber reads each repeat request personally (a real clinician, not a checkbox system) and looks at your current dose, side-effect history and weight trajectory before confirming any increase.
On the "wait" side: persistent nausea or vomiting that hasn't settled, significant digestive discomfort, or a recent bout of illness that's affected how much you've been eating or drinking. Moving up while your system is unsettled tends to intensify symptoms rather than skip past them. Staying at a dose for eight or even twelve weeks instead of four is clinically reasonable and sometimes the smarter call.
It is also worth knowing that the decision to increase is never automatic even when the timing looks right. Dose escalation is a shared decision, your experience of the current dose matters as much as the four-week marker.
Once you've worked through 2.5mg and 5mg, the same four-week minimum and clinical-review principle applies at every subsequent step: 7.5mg, 10mg, 12.5mg, and 15mg. The goal is to reach the dose at which your appetite suppression and weight loss are adequate, with side effects you can live with. That is not necessarily the highest dose on the label.
Some people do very well at 7.5mg or 10mg and see no clinical reason to push further. Others need the higher doses to achieve meaningful progress. Whether 7.5mg is the right next step for you depends on your current results, how you've felt at 5mg, and your prescriber's assessment. NICE's appraisal of tirzepatide notes that if less than five per cent weight loss occurs after six months at the highest tolerated dose, continuing treatment is reviewed, see NICE TA1026 for the full recommendations. That context is useful: the aim is the highest dose that is both effective and tolerable, not the highest dose that exists.
If you're thinking about the timing of dose increases more broadly, the cost of treatment across dose levels is a practical consideration too, and our guide on when you should up your dose of Mounjaro walks through how to think about that alongside the financial side. You can also find a plain breakdown on the Mounjaro pricing page.
On the NHS, dose increases happen within a structured multidisciplinary programme. In a private setting, that clinical rigour still has to exist, the legal and professional obligations on a prescribing pharmacist don't change based on who's paying. At nume, every dose increase requires a clinical re-review. We don't auto-ship a higher dose; you submit your progress, and a prescriber confirms the increase is appropriate before anything is dispatched.
That process protects you. It also means that if you feel ready for an increase but your prescriber disagrees, there will be a clear clinical reason. Questioning that is reasonable, and our aftercare team is reachable seven days a week if you want to discuss where you are. The FAQs page covers a lot of common dose questions, and you can also browse our wider weight-loss information for context on how treatment fits into a longer-term approach.
If you're ready to discuss your current dose or start treatment from scratch, speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.